June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Preventing relapses and chorioretinal neovascularization in EAU with a novel small molecule suppressing rat and human T cells, but not retinal pigment epithelial cells
Author Affiliations & Notes
  • Stephan R Thurau
    Clinic of the University of Munich, Munich, Germany
  • Maria Diedrichs-Möhring
    Clinic of the University of Munich, Munich, Germany
  • Claudia Priglinger
    Clinic of the University of Munich, Munich, Germany
  • Franz Obermayr
    Panoptes Pharma, Wien, Austria
  • Gerhild Wildner
    Clinic of the University of Munich, Munich, Germany
  • Footnotes
    Commercial Relationships   Stephan Thurau, AbbVie (R), Panoptes Pharma (C), Pharm Allergan (R), Santen (R); Maria Diedrichs-Möhring, Panoptes Pharma (F); Claudia Priglinger, None; Franz Obermayr, Panoptes Pharma (E); Gerhild Wildner, AbbVie (R), Panoptes Pharma (F), Pharm Allergan (R)
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 532. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Stephan R Thurau, Maria Diedrichs-Möhring, Claudia Priglinger, Franz Obermayr, Gerhild Wildner; Preventing relapses and chorioretinal neovascularization in EAU with a novel small molecule suppressing rat and human T cells, but not retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 2017;58(8):532.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Experimental autoimmune uveitis (EAU) in rats is a suitable model for the respective intraocular inflammatory disease in humans. We investigated the in vivo effect of the small molecule dihydroorotate dehydrogenase inhibitor PP-001 in spontaneously relapsing-remitting and monophasic/chronic EAU with chorioretinal neovascularization and in vitro on rat and human lymphocytes and human RPE cells.

Methods : Lewis rats were immunized with S-Antigen peptide PDSAg or interphotoreceptor retinoid-binding protein peptide R14 to induce monophasic or relapsing EAU, respectively. PP-001 was fed daily or injected intraocularly once. Uveitis was graded clinically and histologically, neovascularization was determined by histology. Rat lymph node cells and human peripheral lymphocytes of a healthy donor were stimulated with PHA and coincubated with PP-001. The human RPE cell line ARPE 19 and primary human RPE cells were cocultured with PP-001 or anti-VEGF, cytokines in culture supernatants were measured by bioplex bead assay.

Results : Daily oral treatment with PP-001 after onset or peak of EAU induced with retinal S-Antigen peptide PDSAg (monophasic uveitis) significantly reduced neovascularization. A significant reduction of the number and intensity of relapses in R14-induced EAU was observed when daily oral PP-001 treatment was initiated or a single intraocular injection performed after resolution of the first attack of uveitis. Proliferation of autoantigen-specific rat T-cell lines and secretion of IFN-γ, IL-17, IL-10, IP-10 and VEGF were efficiently suppressed by PP-001. PP-001 also suppressed proliferation and cytokine secretion of PHA-stimulated human PBL without affecting the viability of the cells. Treating the human retinal pigment epithelial cell line ARPE-19 with PP-001 no suppressive effect on proliferation, viability and VEGF production was observed, in contrast to treatment with anti-VEGF bevacizumab. PP-001 showed no toxic effect on rat eye tissues after intraocular injection.

Conclusions : Here we present a novel drug for systemic and local treatment of autoimmune uveitis without adverse effects on resident ocular cells. Furthermore, our data show that neovascularization as a sequel in uveitis can be caused by VEGF-producing autoreactive T cells only and not by RPE.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×